BioMarin Prepares To Launch Roctavian For Hemophilia In An Uncertain Environment

The company lowered revenue guidance due to COVID-19, but announced a new brand name, Roctavian, for its hemophilia A gene therapy, which it said remains on track for FDA approval later this year.